联合抑制GLUT1与OXPHOS通过限制代谢可塑性清除急性髓系白血病细胞
本研究在小鼠MLL::AF9驱动急性髓系白血病(AML)模型中进行体内CRISPR敲除筛选,发现葡萄糖转运体1(GLUT1)是白血病干细胞(LSC)的关键体内代谢依赖。遗传或药物抑制GLUT1可抑制白血病进展并延长移植小鼠生存,且联合抑制GLUT1与氧化磷酸化(OXPHOS)在多数原代AML患者样本中表现协同抗白血病效应。
要点
- 体内CRISPR筛选鉴定GLUT1为小鼠MLL::AF9 AML模型中LSC的关键代谢依赖。
- 抑制GLUT1可抑制糖酵解、改变代谢谱并诱导自噬与凋亡,伴AML细胞分化相关改变。
- GLUT1与OXPHOS双重抑制在多数原代AML样本中协同,RUNX1突变细胞尤为敏感。
核心结论
- 研究揭示小鼠骨髓微环境中LSC对GLUT1的依赖,并表明GLUT1与OXPHOS双重抑制是AML有前景的治疗策略。
研究设计与样本
- 在小鼠MLL::AF9驱动AML模型中进行体内CRISPR敲除筛选,检测LSC的细胞表面依赖。
- 采用遗传敲除或药物抑制GLUT1,并在移植LSC的小鼠中评估白血病进展与生存。
- 对原代AML患者样本进行GLUT1与OXPHOS双重抑制,并与正常CD34+骨髓及脐血细胞比较。
主要发现
- GLUT1是LSC的关键体内代谢依赖,遗传敲除或药物抑制GLUT1可抑制白血病进展并改善移植小鼠生存。
- 抑制Glut1可抑制糖酵解、降低三羧酸循环中间产物水平并升高氨基酸水平。
- 该代谢重编程伴随自噬活性与凋亡增加,并出现转录、形态及免疫表型改变,符合AML细胞分化。
- GLUT1与OXPHOS双重抑制在多数受试原代AML患者样本中表现协同抗白血病效应。
- RUNX1突变的原代白血病细胞对联合治疗表现出显著敏感性,对比正常CD34+骨髓与脐血细胞。
临床怎么用
- 原文结论认为GLUT1与OXPHOS双重抑制是AML有前景的治疗策略,未给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is initiated and propagated by leukemia stem cells (LSCs), a self-renewing population of leukemia cells responsible for therapy resistance. Hence, there is an urgent need to identify new therapeutic opportunities targeting LSCs. Here, we performed an in vivo CRISPR knockout screen to identify potential therapeutic targets by interrogating cell surface dependencies of LSCs. The facilitated glucose transporter type 1 (GLUT1) emerged as a critical in vivo metabolic dependency for LSCs in a murine MLL::AF9-driven model of AML. GLUT1 disruption by genetic ablation or pharmacological inhibition led to suppression of leukemia progression and improved survival of mice that received transplantation with LSCs. Metabolic profiling revealed that Glut1 inhibition suppressed glycolysis, decreased levels of tricarboxylic acid cycle intermediates and increased the levels of amino acids. This metabolic reprogramming was accompanied by an increase in autophagic activity and apoptosis. Moreover, Glut1 disruption caused transcriptional, morphological, and immunophenotypic changes, consistent with differentiation of AML cells. Notably, dual inhibition of GLUT1 and oxidative phosphorylation (OXPHOS) exhibited synergistic antileukemic effects in the majority of tested primary AML patient samples through restraining of their metabolic plasticity. In particular, RUNX1-mutated primary leukemia cells displayed striking sensitivity to the combination treatment compared with normal CD34+ bone marrow and cord blood cells. Collectively, our study reveals a GLUT1 dependency of murine LSCs in the bone marrow microenvironment and demonstrates that dual inhibition of GLUT1 and OXPHOS is a promising therapeutic approach for AML.
引用
- Rodriguez-Zabala M, Ramakrishnan R, Reinbach K, et al. Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity. Blood Adv. 2023. PMID: 37505194. doi:10.1182/bloodadvances.2023009967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。